NCT Number: NCT04328298
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Interested in participating?
Request InfoKey information
Age range
0 year–99 year
Sex eligibility
All sexes
Study type
Observational
Primary location
CHU d'Amiens - Hôpital Sud, Amiens, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Retrospective inclusion :
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
Prospective inclusion :
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
Exclusion criteria
Patient not registered with the social security in France
Treatment and study plan
Primary outcomes
-
overall survival from eligibility
Time frame: 15 years
-
Overall survival from administration
Time frame: 15 years
-
complete response rate
Time frame: 15 years
-
Progression free survival
Time frame: 15 years
-
Duration of response
Time frame: 15 years
-
Delays between patient eligibility and CAR-T treatment
Time frame: 15 years
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
The Lymphoma Academic Research Organisation
Other
Collaborators
- Bristol-Myers Squibb
- Gilead Sciences
- Novartis
Registry information
Important dates
- Study start
- 2019
- Primary completion
- 2038
- Study completion
- 2038
- First posted
- Mar 31, 2020
- Registry last updated
- Mar 4, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.